Objectives. To evaluate the validity of patient report, pharmacy dispensing records, and pill counts as measures of antihypertensive adherence using electronic monitoring as the validation standard.
Methods. The study was conducted among 286 members of Harvard Pilgrim Health Care, a managed care organization, who were at least 18 years of age, on monotherapy for hypertension, and had prescription drug coverage. Prescription refill adherence during the 12 months before enrollment was determined from their automated pharmacy dispensing records. Participants were interviewed about their medication adherence before and after a 3-month electronic monitoring period during which pill counts were also performed. Adherence to both recommended number and timing of doses was estimated from electronic monitoring data. Data analysis was based on statistical correlation and analysis of variance.
Results. Electronic adherence monitoring revealed that the proportion of prescribed doses consumed was higher (0.92) than the proportion of doses taken on time (0.63). The correlation between adherence to quantity and timing of doses was 0.32. Concurrent pill counts and earlier refilling patterns were moderately correlated with electronic monitoring (pill count: r = .52 with quantity and r = .17 with timing; refill adherence r = .32 with quantity and r = .22 with timing). There was considerable misclassification of adherence reported by patients, although nonadherence was generally accurately reported.
Conclusions. Deviation from recommended timing of doses appears to be greater than from prescribed number of doses. Pharmacy dispensing records demonstrate predictive validity as measures of cumulative exposure and gaps in medication supply. Adherence levels determined from pill counts and pharmacy dispensing records correlate more closely with quantity than with timing of doses. Nonadherence reported by patients can serve as a qualitative indicator and predictor of reduced adherence.
*From the Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
†From the Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, Massachusetts.
‡From the Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts.
§From the Johns Hopkins Asthma and Allergy Center, Johns Hopkins School of Medicine, Baltimore, Maryland.
This study was supported by a research grant from the Agency for Health Care Policy and Research, # HS07821, and institutional support from the Harvard Pilgrim Health Care Foundation
Address correspondence to: Peter W. Choo, MD, DrPH, 181 Longwood Avenue, Room 433, Boston, MA 02115.
Received August 6, 1998; initial review completed October 9, 1998; accepted March 4, 1999.